Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 2022 First -half results July 29th, 2022
2022 First -half results
2.Strong growth in sales
3.Very solid results despite an unstable and highly inflationary environment
4.2 new bolt -on acquisitions in datacenters announced
5.2022 full -year target for sales raised
6.AppendicesContents2022 First -half results 3
Strong growth in sales +18.5%
•Including organic growth +10.9%
Very solid results despite an unstable and highly inflationary environment
•Adjusted operating margin 20.5% of sales
•Rise in net profit +13.9%
2 new bolt -on acquisitions in datacenters announced
2022 full -year target for sales raised
•Total growth at constant FX +9% to +12%5
Strong growth in sales6
6H1 2021 H1 2022+10.9%
FX(2)€ millionsStrong growth in sales
H1 2022 change in net sales
1.Based on acquisitions completed, and their probable dates of consolidation, the impact of the scope of consolidation should b e around +3% of full -year 2022 sales.
2.Based on the monthly average exchange rates of June 2022 alone, the full -year exchange rate effect on sales for 2022 should be c lose to +4.5%.7
7Strong growth in sales
H1 2022 sales by destination
41.5% OFGROUPNORTH & CENTRAL AMERICA
39.1% OFGROUPREST OF THE WORLD
MATURE COUNTRIES (35.9% of Group)
H1 +9.5% with Q2 +9.1%
H1 +22.5% with Q2 +13.8%
•Over Q2, negative impact of the
conflict between Russia & Ukraine
•Ukraine & Russia together: ~2%
Preview truncated — download the full document for the complete content.
infographic
investor_presentation
26 Pages
Premier Explosives Limited
Regeneron Pharmaceuticals Investor Presentation — September 2022
investor_presentationinvestor_presentation
42 Pages
Regeneron Pharmaceuticals, Inc.
investor_presentation
DocuSign